Verastem, Inc.
117 Kendrick Street
Suite 500
Needham, MA 02494
United States
781 292 4200
https://www.verastem.com
版塊: Healthcare
行業: Biotechnology
全職員工: 73
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Daniel W. Paterson | President, CEO & Director | 897.59k | 無 | 1961 |
| Mr. Daniel Calkins | CFO and Principal Accounting & Financial Officer | 401.83k | 無 | 1988 |
| Mr. Richard H. Aldrich M.B.A. | Founder and Consultant | 38.39k | 無 | 1954 |
| Dr. Robert A. Weinberg Ph.D. | Co-Founder & Chair of Scientific Advisory Board | 無 | 無 | 無 |
| Dr. Piyush B. Gupta Ph.D. | Co-Founder | 無 | 無 | 無 |
| Dr. Michelle Dipp M.D., Ph.D. | Co-Founder | 無 | 無 | 1976 |
描述
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.
公司管治
截至 2024年5月1日 止，Verastem, Inc. 的 ISS 管治質素評分為 8。 Pillar 分數正在審核中：7；董事會：8；股東權利：7；現金賠償：9。
